MX2019008438A - Moduladores del receptor de estrogeno. - Google Patents

Moduladores del receptor de estrogeno.

Info

Publication number
MX2019008438A
MX2019008438A MX2019008438A MX2019008438A MX2019008438A MX 2019008438 A MX2019008438 A MX 2019008438A MX 2019008438 A MX2019008438 A MX 2019008438A MX 2019008438 A MX2019008438 A MX 2019008438A MX 2019008438 A MX2019008438 A MX 2019008438A
Authority
MX
Mexico
Prior art keywords
estrogen receptor
receptor modulators
5and
compounds
processes
Prior art date
Application number
MX2019008438A
Other languages
English (en)
Inventor
Yang Bin
Christophe Barlaam Bernard
Wilhelmus Maria Nissink Johannes
Andrew Moss Thomas
Jayne Hughes Samantha
Stewart Scott James
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2019008438A publication Critical patent/MX2019008438A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La memoria descriptiva se refiere a compuestos de Fórmula (I): (ver fórmula), (I) y a sales farmacéuticamente aceptables de estos, a procesos e intermedios utilizados para su preparación, a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de trastornos celulares proliferativos.
MX2019008438A 2017-01-30 2018-01-29 Moduladores del receptor de estrogeno. MX2019008438A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762451971P 2017-01-30 2017-01-30
US201762523695P 2017-06-22 2017-06-22
US201762560304P 2017-09-19 2017-09-19
US201762592485P 2017-11-30 2017-11-30
PCT/EP2018/052040 WO2018138303A1 (en) 2017-01-30 2018-01-29 Estrogen receptor modulators

Publications (1)

Publication Number Publication Date
MX2019008438A true MX2019008438A (es) 2019-10-30

Family

ID=61223883

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008438A MX2019008438A (es) 2017-01-30 2018-01-29 Moduladores del receptor de estrogeno.

Country Status (36)

Country Link
US (3) US10221173B2 (es)
EP (2) EP3689873B1 (es)
JP (1) JP6951451B2 (es)
KR (1) KR102246668B1 (es)
CN (1) CN110214140B (es)
AU (1) AU2018211495B2 (es)
BR (1) BR112019015389A2 (es)
CA (1) CA3050337A1 (es)
CL (1) CL2019001991A1 (es)
CO (1) CO2019008941A2 (es)
CR (1) CR20190379A (es)
CY (1) CY1122731T1 (es)
DK (1) DK3494116T3 (es)
DO (1) DOP2019000183A (es)
EC (1) ECSP19062381A (es)
ES (2) ES2931320T3 (es)
HU (1) HUE047761T2 (es)
IL (1) IL268263B (es)
JO (1) JOP20190183B1 (es)
LT (1) LT3494116T (es)
MA (1) MA52555A (es)
MX (1) MX2019008438A (es)
MY (1) MY196317A (es)
NI (1) NI201900080A (es)
PE (1) PE20191500A1 (es)
PH (1) PH12019501724A1 (es)
PL (1) PL3494116T3 (es)
PT (1) PT3494116T (es)
RS (1) RS59770B1 (es)
SG (1) SG11201906767XA (es)
SI (1) SI3494116T1 (es)
TN (1) TN2020000009A1 (es)
TW (1) TWI794205B (es)
UA (1) UA125043C2 (es)
WO (1) WO2018138303A1 (es)
ZA (1) ZA201904696B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018015419B1 (pt) 2016-02-05 2024-01-30 Inventisbio Llc Degradantes seletivos de receptor de estrogênio, seus usos, e composição farmacêutica
WO2018112379A1 (en) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Small molecule inhibitors of the jak family of kinases
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
US20220370625A1 (en) * 2019-09-19 2022-11-24 Totus Medicines Inc. Therapeutic conjugates
CN115557920B (zh) * 2022-09-22 2024-02-20 吉林奥来德光电材料股份有限公司 一种发光辅助材料、其制备方法及有机电致发光器件

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EA006381B1 (ru) 2000-08-10 2005-12-29 Фармация Италия С.П.А. Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
WO2005111208A1 (ja) * 2004-04-27 2005-11-24 Chugai Seiyaku Kabushiki Kaisha プラズマ細胞の増殖方法
WO2006101434A1 (en) 2005-03-22 2006-09-28 Astrazeneca Ab NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS
FR2884252B1 (fr) 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
AR058223A1 (es) 2005-11-25 2008-01-23 Palau Pharma Sa Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto
JP2010505961A (ja) 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US20120157402A1 (en) 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
CA2999345A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
CN102939287B (zh) 2010-06-10 2016-01-27 塞拉根制药公司 雌激素受体调节剂及其用途
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
LT3004090T (lt) * 2013-05-28 2018-01-10 Astrazeneca Ab Cheminiai junginiai
WO2014205138A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
KR20230113416A (ko) * 2014-12-18 2023-07-28 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체조절제 및 이의 용도
US20160175284A1 (en) 2014-12-18 2016-06-23 Genentech, Inc. Estrogen receptor modulators and uses thereof
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
JP6768711B2 (ja) 2015-05-26 2020-10-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 複素環式エストロゲン受容体モジュレーター及びその使用
MX2017016376A (es) 2015-06-16 2018-03-02 Jiangsu Hengrui Medicine Co Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
CN106518768B (zh) 2015-09-15 2021-07-02 江苏恒瑞医药股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的应用
KR20180071274A (ko) 2015-10-01 2018-06-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
CN108349952A (zh) 2015-11-09 2018-07-31 豪夫迈·罗氏有限公司 四氢萘雌激素受体调节剂及其用途
US10519148B2 (en) 2015-11-12 2019-12-31 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
CN107428721B (zh) 2015-12-22 2020-07-28 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物、其制备方法及其在医药上的应用
EP3440067B1 (en) 2016-04-08 2021-05-26 F. Hoffmann-La Roche AG Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
WO2017192991A1 (en) 2016-05-06 2017-11-09 Xavier University Of Louisiana Selective estrogen receptor down-regulators (serds)
WO2018001232A1 (zh) 2016-06-29 2018-01-04 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
WO2018019793A1 (en) * 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
CN107814798B (zh) 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
EP3512842B1 (en) 2016-09-15 2024-01-17 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
US10131663B2 (en) 2016-10-24 2018-11-20 Astrazeneca Ab Chemical compounds
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
LT3555105T (lt) 2016-12-16 2021-01-11 Eli Lilly And Company 7-feniletilamino-4h-pirimido[4,5-d][1,3]oksazin-2-ono junginiai kaip mutantiniai idh1 ir idh2 slopikliai
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
DK3555064T5 (da) 2016-12-16 2023-05-01 Pfizer GLP-1 receptoragonister og anvendelser deraf
WO2018112379A1 (en) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Small molecule inhibitors of the jak family of kinases
US20200077658A1 (en) 2016-12-16 2020-03-12 Basf Se Pesticidal Compounds
WO2018138293A1 (en) 2017-01-30 2018-08-02 Chiesi Farmaceutici S.P.A. Tyrosine amide derivatives as rho- kinase inhibitors

Also Published As

Publication number Publication date
PT3494116T (pt) 2020-01-28
WO2018138303A1 (en) 2018-08-02
TN2020000009A1 (en) 2021-10-04
ES2766249T3 (es) 2020-06-12
US20190233413A1 (en) 2019-08-01
MA52555A (fr) 2021-03-17
CN110214140A (zh) 2019-09-06
CY1122731T1 (el) 2021-05-05
CR20190379A (es) 2019-10-21
MY196317A (en) 2023-03-24
HUE047761T2 (hu) 2020-05-28
KR102246668B1 (ko) 2021-04-29
TWI794205B (zh) 2023-03-01
CN110214140B (zh) 2022-08-30
EP3689873A1 (en) 2020-08-05
ECSP19062381A (es) 2019-09-30
CO2019008941A2 (es) 2019-08-30
JP6951451B2 (ja) 2021-10-20
SI3494116T1 (sl) 2020-02-28
CL2019001991A1 (es) 2019-10-11
PE20191500A1 (es) 2019-10-22
IL268263B (en) 2021-10-31
DK3494116T3 (da) 2020-01-27
EP3689873B1 (en) 2022-09-14
CA3050337A1 (en) 2018-08-02
IL268263A (en) 2019-09-26
EP3494116A1 (en) 2019-06-12
TW201840558A (zh) 2018-11-16
JOP20190183B1 (ar) 2022-09-15
UA125043C2 (uk) 2021-12-29
NI201900080A (es) 2020-03-18
LT3494116T (lt) 2020-01-10
US10590132B2 (en) 2020-03-17
ZA201904696B (en) 2020-05-27
US20180282325A1 (en) 2018-10-04
US10221173B2 (en) 2019-03-05
US11046689B2 (en) 2021-06-29
PL3494116T3 (pl) 2020-04-30
PH12019501724A1 (en) 2020-06-01
RS59770B1 (sr) 2020-02-28
SG11201906767XA (en) 2019-08-27
EP3494116B1 (en) 2019-10-23
AU2018211495A1 (en) 2019-09-12
DOP2019000183A (es) 2019-07-31
JP2020505354A (ja) 2020-02-20
BR112019015389A2 (pt) 2020-03-10
AU2018211495B2 (en) 2020-05-21
KR20190112767A (ko) 2019-10-07
US20200239468A1 (en) 2020-07-30
ES2931320T3 (es) 2022-12-28
JOP20190183A1 (ar) 2019-07-28

Similar Documents

Publication Publication Date Title
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
JOP20210241A1 (ar) مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
TN2020000009A1 (en) Estrogen receptor modulators
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
CA2912921C (en) Pyrazole compounds as modulators of fshr and uses thereof
PH12021550048A1 (en) Selective estrogen receptor degraders.
TW201613864A (en) Novel compounds
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
WO2015138276A3 (en) Retinoic acid receptor-related orphan receptor modulators and uses thereof
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
MX2018009078A (es) Derivados de indano como moduladores mglur7.
TW201613921A (en) Serine derivatives as ghrelin receptor agonists
MX2016011900A (es) Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
WO2015138280A3 (en) Retinoic acid receptor-related orphan receptor modulators and uses thereof
MX2021004471A (es) Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1.
EA201991734A1 (ru) Модуляторы рецептора эстрогена
EA202092600A1 (ru) Тетрациклические гетероарильные соединения
NZ764561A (en) Substituted azacycles as muscarinic m1 receptor positive allosteric modulators